BIOMAT Database Logo BIOMAT Database Logo

Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV). 2011

Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
WHO-Collaborating Center for Reference & Research on Rabies, Pasteur Institute of Iran, Tehran, Iran. fayaz@pasteur.ac.ir

In 1975-1976 forty-five persons severely bitten by rabid wolves and dogs in Iran were treated successfully against rabies with HDCV. In this study contact was made with 26 of 45 above persons, 32 years after their initial treatment and all had rabies neutralizing antibody ranging from 0.3 to 2.69 IU/ml of serum. Of the 26 persons, 17 had received a booster dose of HDCV, 28 years ago and the remaining 9 persons, who had not received any booster since the initial treatment, were given one booster dose of HDCV. All 9 of these patients developed an anamnestic response after their booster inoculation. This study confirms the persistence of rabies neutralizing antibody in persons that received post-exposure vaccination with HDCV, 32 years previously. Furthermore, a single booster inoculation with HDCV resulted in anamnestic response in all individuals.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011818 Rabies Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf. Encephalitic Rabies,Furious Rabies,Hydrophobia,Paralytic Rabies,Lyssa,Furious Raby,Lyssas,Rabies, Encephalitic,Rabies, Furious,Raby, Furious
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D011820 Rabies virus The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates. Rabies viruses
D001733 Bites and Stings Injuries inflicted by the TEETH or poisoning caused by VENOMS of animals. Stings,Bites,Stings and Bites,Bite,Sting
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Persistence of rabies antibody 5 years after pre-exposure prophylaxis with human diploid cell antirabies vaccine and antibody response to a single booster dose.
August 1987, Epidemiology and infection,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Post-exposure prophylaxis against rabies in children with human diploid cell vaccine.
August 1982, Lancet (London, England),
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Clinical trial with an anti-rabies human diploid cell vaccine (HDCV).
January 1978, Developments in biological standardization,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Rabies postexposure prophylaxis with human diploid cell rabies vaccine: lower neutralizing antibody titers with Wyeth vaccine.
February 1985, MMWR. Morbidity and mortality weekly report,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Post-exposure use of human diploid cell culture rabies vaccine.
January 1976, Developments in biological standardization,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Human diploid cell strain vaccine for post-exposure rabies treatment.
March 1985, The Journal of communicable diseases,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis.
August 1983, Lancet (London, England),
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Human diploid-cell-culture vaccine for rabies prophylaxis.
May 1979, Canadian Medical Association journal,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
[Antibody response in patients vaccincated with anti-rabies vaccine Vnukovo-32 and HDCV Mérieux].
September 1985, Ceskoslovenska epidemiologie, mikrobiologie, imunologie,
Ahmad Fayaz, and Susan Simani, and Alireza Janani, and Firouzeh Farahtaj, and Peyvand Biglari, and Nader Howeizi, and Nasser Eslami
Pre-exposure prophylaxis against rabies in children by human diploid cell vaccine.
March 1984, Lancet (London, England),
Copied contents to your clipboard!